SubHero Banner

Kedrab (rabies immune globulin [human]) – New drug approval

August 25, 2017 – Kedrion Biopharma and Kamada announced the FDA approval of Kedrab (rabies immune globulin [human]), indicated for passive, transient post-exposure prophylaxis of rabies infection, when given immediately after contact with a rabid or possibly rabid animal. Kedrab should be administered concurrently with a full course of rabies vaccine.

Download PDF